FPRX stock forecast
Our latest prediction for Five Prime Therapeutics, Inc.'s stock price was made on the Dec. 9, 2019 when the stock price was at 3.89$.
In the short term (2weeks), FPRX's stock price should underperform the market by -2.75%. During that period the price should oscillate between -11.28% and +14.15%.
In the medium term (3months), FPRX's stock price should underperform the market by -16.09%. During that period the price should oscillate between -38.91% and +29.45%.Get email alerts
About Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.
At the moment the company generates 16M USD in revenues.
On its last earning announcement, the company reported a loss of -4.15$ per share.
The book value per share is 9.47$
Three months stock forecastDec. 9, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|